Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo
      loading

      Chapter

      Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo

      DOI link for Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo

      Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo book

      Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo

      DOI link for Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo

      Targeted Conversion of the Transthyretin Gene In Vitro and In Vivo book

      ByM. Nakamura, Y. Ando, M. Ueda, T. Kawaji, T. Yamashita, J.M. Kim, K. Haraoka, H. Terazaki, S. Nagahara, A. Sano, S. Saito, M. Uchino
      BookAmyloid and Amyloidosis

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2004
      Imprint CRC Press
      Pages 2
      eBook ISBN 9780429125249
      Share
      Share

      ABSTRACT

      Familial amyloidotic polyneuropathy (FAP) is the common form of hereditary generalized amyloidosis and is characterized by the accumulation of amyloid fibrils in the peripheral nerves and other organs. Liver transplantation has been utilized as therapy for FAP, because the variant transthyretin (TTR) is predominantly synthesized by the liver, but this therapy is associated with several problems. The level of gene conversion was determined by real-time RCR combined with mutant-allele-specific amplification. Kren et al. reported that genomic and phenotypic changes that were induced by targeted gene repair were stable during an 18-month period, which suggests that the effect of targeted gene repair could be permanent and that this method might be effective for genomic TTR therapy. Gene therapy via fit-point method may therefore be a promising alternative to liver transplantation for treatment of FAP.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited